AGL — agilon health, inc. Stock Price, Chart & AI Report

Negative Mar 1, 2026 • 23:17 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

AGILON CLASS ACTION DEADLINE MARCH 2nd: Bragar Eagel & Squire, P.C. Urgently Reminds Agilon Health Investors with Large Losses to Contact the Firm Before the Lead Plaintiff Deadline

A class action lawsuit has been filed against Agilon Health, Inc. (NYSE: AGL) for allegedly making false and misleading statements regarding 2025 guidance and overstating financial impacts from strategic actions. Investors who purchased Agilon securities between February 26, 2025 and August 4, 2025 have until March 2, 2026 to apply as lead plaintiff.

AGL class action lawsuit securities fraud false guidance investor losses lead plaintiff deadline misleading statements

Sentiment note

The company is accused of issuing false 2025 guidance, overstating financial impacts from strategic actions, and making materially misleading statements about its business operations and prospects, resulting in investor losses.

Negative Feb 27, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges agilon health, inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against agilon health, inc. alleging that company executives made false and misleading statements regarding 2026 guidance and overstated the financial impact of strategic risk reduction actions during the period from February 26, 2025 to August 4, 2025. Investors who purchased agilon securities during this period are encouraged to join the case, with a lead plaintiff deadline of March 2, 2026.

AGL class action lawsuit securities fraud false guidance investor harm lead plaintiff federal securities laws

Sentiment note

Company is accused of issuing false 2026 guidance, overstating financial benefits from strategic actions, and making materially misleading statements about business operations and prospects, resulting in investor losses.

Negative Feb 24, 2026 • 22:43 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

AGILON DEADLINE MARCH 2nd: Bragar Eagel & Squire, P.C. Urgently Reminds Agilon Health Investors with Larges Losses to Contact the Firm Before the Lead Plaintiff Deadline

A class action lawsuit has been filed against Agilon Health, Inc. for allegedly making false and misleading statements regarding 2025 guidance and overstating financial impacts from strategic actions. Investors who purchased Agilon securities between February 26, 2025 and August 4, 2025 have until March 2, 2026 to apply as lead plaintiff.

AGL class action lawsuit securities fraud misleading statements investor losses lead plaintiff deadline false guidance

Sentiment note

The company is accused of issuing false 2025 guidance, overstating financial impacts from strategic actions, and making materially misleading statements about its business operations and prospects, resulting in investor losses.

Negative Feb 24, 2026 • 21:52 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in agilon health, inc. of Class Action Lawsuit and Upcoming Deadlines - AGL

Pomerantz Law Firm has filed class action lawsuits against agilon health, inc. and other companies for alleged securities fraud. Agilon's CEO stepped down on August 4, 2025, and the company suspended its 2025 financial guidance, citing acute industry headwinds. The stock fell 51.52% to $0.88 per share on August 5, 2025. Investors have until March 2, 2026 to request Lead Plaintiff status.

AGL class action lawsuit securities fraud CEO resignation financial guidance suspension stock price decline

Sentiment note

CEO departure, suspension of full-year 2025 financial guidance, acknowledgment of worse-than-expected industry headwinds, and a dramatic 51.52% stock price decline indicate significant operational and financial challenges, along with alleged securities fraud.

Negative Feb 21, 2026 • 14:50 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A HIGHLY RANKED LAW FIRM, Encourages PomDoctor Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - POM

Rosen Law Firm is soliciting investors who purchased securities in PomDoctor Ltd., Richtech Robotics Inc., and agilon health, inc. during specified periods to join class action lawsuits. The firm alleges that PomDoctor was subject to fraudulent stock promotion schemes and misleading statements, while similar allegations are being pursued against the other companies. The lead plaintiff deadline for PomDoctor is April 7, 2026.

POM RR AGL securities class action fraudulent stock promotion misleading statements lead plaintiff deadline investor compensation

Sentiment note

Company is subject to securities class action lawsuit with the firm specifically targeting investors with losses exceeding $100,000, indicating material investor harm.

Negative Feb 21, 2026 • 14:31 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, THE FIRST FILING FIRM, Encourages Richtech Robotics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – RR

Rosen Law Firm has filed securities class action lawsuits against Richtech Robotics Inc. (RR), PomDoctor Ltd. (POM), and agilon health, inc. (AGL). The primary case involves Richtech Robotics, which allegedly made false statements about having a collaborative relationship with Microsoft. Investors who purchased securities during specified class periods are encouraged to seek counsel before upcoming deadlines, with the lead plaintiff deadline for Richtech set for April 3, 2026.

RR POM AGL securities class action Richtech Robotics PomDoctor Ltd. agilon health false statements

Sentiment note

Company is subject to a securities class action lawsuit with the firm specifically noting investors with losses in excess of $100K, indicating significant alleged securities violations.

Negative Feb 21, 2026 • 13:45 UTC GlobeNewswire Inc. • Rosen Law Firm

AGILON DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages agilon health, inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AGL

Rosen Law Firm is soliciting investors who purchased securities of Agilon Health (AGL) between February 26, 2025 and August 4, 2025 to join a securities class action lawsuit. The firm alleges that Agilon made false and misleading statements regarding 2025 guidance, overstated financial impacts from strategic actions, and failed to disclose material industry headwinds. The lead plaintiff deadline is March 2, 2026. Similar class action notices are being issued for Beyond Meat and Phoenix Education Partners.

AGL BYND PXED securities class action false guidance misleading statements investor losses lead plaintiff deadline

Sentiment note

Company is subject to securities class action lawsuit alleging reckless issuance of unachievable 2025 guidance, material overstatement of financial impacts from strategic actions, and failure to disclose known industry headwinds. These allegations suggest management misconduct and potential investor harm.

Negative Feb 20, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges agilon health, inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against agilon health, inc. (NYSE: AGL) alleging that company executives made false and misleading statements regarding 2026 guidance and overstated the financial impact of strategic risk-reduction actions. The lawsuit covers investors who purchased agilon securities between February 26, 2025 and August 4, 2025. The lead plaintiff deadline is March 2, 2026.

AGL class action lawsuit securities fraud false guidance investor harm agilon health

Sentiment note

Company is accused of issuing false 2026 guidance, overstating financial benefits from strategic actions, and making materially misleading statements about business operations and prospects, resulting in investor losses and a securities fraud class action lawsuit.

Negative Feb 19, 2026 • 23:00 UTC GlobeNewswire Inc. • Kirby Mcinerney Llp

AGL DEADLINE NOTICE: agilon health, inc. Investors Encouraged to Contact Kirby McInerney LLP By March 2, 2026

A securities fraud class action lawsuit has been filed against agilon health, inc. for allegedly issuing false 2025 guidance and overstating the impact of strategic actions despite known industry headwinds. The CEO was terminated without cause on August 4, 2025, the same day the company suspended its full-year 2025 financial guidance. The stock price declined 51.6% following the announcement. Investors have until March 2, 2026 to apply to be lead plaintiff.

AGL securities fraud class action lawsuit false guidance CEO termination stock price decline financial misstatement lead plaintiff deadline

Sentiment note

The company is the subject of a securities fraud lawsuit alleging false and misleading statements regarding 2025 guidance and overstated financial impact from strategic actions. The CEO was terminated without cause, full-year guidance was suspended, and the stock experienced a severe 51.6% price decline on the news, indicating significant loss of investor confidence and potential material misstatements.

Negative Feb 19, 2026 • 18:50 UTC GlobeNewswire Inc. • Law Offices Of Howard G. Smith

DEADLINE ALERT for KLAR, AGL, FRMI: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Class action lawsuits have been filed against Klarna Group, agilon health, and Fermi Inc. for alleged securities fraud involving false statements and material omissions. Klarna faces allegations of understating loss reserve risks post-IPO, agilon is accused of issuing unachievable 2025 guidance, and Fermi is charged with overstating tenant demand for its Project Matador campus. Lead plaintiff deadlines range from February 20 to March 6, 2026.

KLAR AGL FRMI securities fraud class action lawsuit false statements material omissions lead plaintiff

Sentiment note

Defendants accused of issuing unachievable 2025 guidance despite known industry headwinds and overstating positive financial impacts from strategic actions.

Negative Feb 17, 2026 • 19:29 UTC GlobeNewswire Inc. • Robbins Llp

Robbins LLP Urges AGL Stockholders with Large Losses to Contact the Firm for Information About Leading the Agilon Health, Inc. Securities Class Action

Robbins LLP has filed a class action lawsuit against Agilon Health, Inc. (AGL) on behalf of investors who purchased securities between February 26, 2025 and August 4, 2025. The firm alleges that Agilon misled investors by issuing unachievable 2025 guidance despite known industry headwinds and overstating the positive impact of strategic risk reduction actions. Following the CEO's departure and disappointing financial results announced on August 4, 2025, AGL's stock price fell over 50%. The lead plaintiff deadline is March 2, 2026.

AGL securities class action investor fraud misleading guidance stock price decline CEO departure financial misstatement

Sentiment note

The company is accused of issuing misleading 2025 guidance despite known industry headwinds, overstating the impact of strategic actions, and failing to disclose material information. The CEO's termination and subsequent 50% stock price decline on disappointing financial results further support the negative sentiment.

Negative Feb 17, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges agilon health, inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against agilon health, inc. (NYSE: AGL) alleging that company executives made false and misleading statements regarding 2026 guidance and overstated the financial impact of strategic risk reduction actions. The lawsuit covers investors who purchased agilon securities between February 26, 2025 and August 4, 2025. The lead plaintiff deadline is March 2, 2026.

AGL class action lawsuit securities fraud false guidance investor harm agilon health

Sentiment note

The company is accused of issuing false 2026 guidance despite knowing of material industry headwinds, materially overstating financial benefits from strategic actions, and making misleading statements about business operations and prospects. These allegations of securities fraud and investor deception warrant a negative sentiment.